Align Technology (NASDAQ:ALGN) Bolsa

ALIGN TECHNOLOGY INC

Align Technology

Align Tech

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

green chart shutter

Analyst Color

Equities

Large Cap

Mid Cap

Price Target

Economics

ALGN

DECK

DELL

FSLR

NCLH

NVDA

SMCI

SNPS

TSLA

¿Es el momento de comprar? Descubre las acciones con mayor potencial de alza según los analistas, incluyendo Tesla, Nvidia y más.

Acciones con mayor potencial de subida en 2025: ¿Cómo se comparan Nvidia (NVDA) y Tesla (TSLA)?

Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares are tumbling in Wednesday&#8217;s after-hours session after the company reported worse-than-expected results for the second quarter and issued soft guidance. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46737999/align-technology-announces-second-quarter-2025-financial-results">of the report</a>.
<ul class="wp-block-list">
<li>Q2 Revenue: 1.01 billion, versus <a href="http://benzinga.com/quote/ALGN/earnings">estimates</a> of $1.06 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q2 Adjusted EPS: $2.49, versus estimates of $2.57</li>
</ul>
<a href="https://www.benzinga.com/quote/ALGN" target="_blank" rel="noreferrer noopener">Track ALGN stock live prices here.</a>
Total revenue was down 1.6% on a year-over-year basis. Clear Aligner revenue of $804.6 million was down 3.3% year-over-year, while Imaging Systems and CAD/CAM Services revenue increased 5.6% year-over-year to $207.8 million.
Align ended the second quarter with $901.2 million in total cash and cash equivalents.
&#8220;During Q2, we continued to see strong consumer interest in Invisalign treatment, as reflected by iTero scans and Invisalign doctor case submissions. However, we experienced uneven patient case conversion, which led to a lower than typical seasonal uptick in case starts, which historically occurs late in the quarter,&#8221; said Joe Hogan, president and CEO of Align.
Align said it repurchased 585,100 shares of its common stock during the quarter at an average price of $164.14 per share.
Outlook: Align expects third-quarter revenue to be between $965 million and $985 million versus estimates of approximately $1.04 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;We are evaluating actions to reduce costs and thoughtfully manage our investments while we continue to drive engagement and effectiveness of commercial and marketing programs that leverage our innovation and new product cycle across our clear aligners and scanners,&#8221; Hogan added.
ALGN Price Action: <a href="http://benzinga.com/quote/ALGN">Align shares</a> were down 36.78% in after-hours, trading at $128.50 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46739502/robinhood-q2-double-beat-crypto-revenue-nearly-doubles">Robinhood Q2: Double Beat, Crypto Revenue Nearly Doubles</a></li>
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46737581/qualcomm-q3-earnings-double-beat-auto-revenue-hits-record">Qualcomm Q3 Earnings: Double Beat, Auto Revenue Hits Record</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/REDPIXELPL">REDPIXEL.PL</a>/Shutterstock.com

Earnings

News

Health Care

Movers

Align Technology Stock Tumbles Wednesday: What's Going On?

<h3>Gainers</h3>
<ul>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock rose 21.4% to $1.05 during Wednesday's after-market session. The company's market cap stands at $17.9 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 18.12% to $0.04. The company's market cap stands at $20.7 million. </li>
<li>Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) stock increased by 16.69% to $15.17. The company's market cap stands at $2.2 billion. As per the press release, Q2 earnings came out today. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares rose 11.8% to $7.29. The market value of their outstanding shares is at $982.9 million. As per the news, the Q2 earnings report came out today. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock rose 7.8% to $10.7. The company's market cap stands at $161.5 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock increased by 6.38% to $1.0. The market value of their outstanding shares is at $14.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) stock declined by 34.7% to $133.0 during Wednesday's after-market session. The company's market cap stands at $14.9 billion. The company's, Q2 earnings came out today. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 14.2% to $2.72. The company's market cap stands at $122.9 million. As per the press release, Q2 earnings came out today. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock decreased by 9.95% to $3.53. The market value of their outstanding shares is at $515.1 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) stock decreased by 9.1% to $1.0. The company's market cap stands at $23.9 million. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock decreased by 7.08% to $1.05. The company's market cap stands at $35.3 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock decreased by 6.39% to $0.84. The company's market cap stands at $24.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALHC

COSM

DYAI

ELTX

HCTI

KAPA

LUNG

MDXG

OSRH

PRME

PTHL

12 Health Care Stocks Moving In Wednesday's After-Market Session

WIIM

Align Technology shares are trading lower after the company missed Q2 earnings estimates and issued soft Q3 guidance.

Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) sees Q3 sales of $965.000 million-$985.000 million vs $1.038 billion analyst estimate.

Guidance

Align Technology Sees Q3 Sales $965.000M-$985.000M vs $1.038B Est

Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) reported quarterly earnings of $2.49 per share which missed the analyst consensus estimate of $2.57 by 3.11 percent. This is a 3.32 percent increase over earnings of $2.41 per share from the same period last year. The company reported quarterly sales of $1.012 billion which missed the analyst consensus estimate of $1.059 billion by 4.43 percent. This is a 1.52 percent decrease over sales of $1.028 billion the same period last year.

Earnings Misses

Align Tech Q2 Adj. EPS $2.49 Misses $2.57 Estimate, Sales $1.012B Miss $1.059B Estimate

ALKT

AMRN

AMSC

ANIK

APLD

ARCB

AWRE

AXTA

BBDO

BLCO

BLFY

BLKB

BSBR

BXMT

CFLT

CGNX

CHEF

CHKP

CHRW

CLMB

CLVT

CMCO

CNMD

CNXN

COCO

COMP

CPSH

CRTO

CTOS

CTSH

CVNA

DXCM

EBAY

New Oriental Education & Technology Group

ENTG

EOSE

EQIX

ETSY

EVTC

EZPW

FBRT

FFIV

FICO

FORM

FRGE

FVRR

GEHC

Earnings Scheduled For July 30, 2025

Evercore ISI Group maintains Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and raises the price target from $200 to $220.

Analyst Ratings

Evercore ISI Group Maintains Outperform on Align Technology, Raises Price Target to $220

<ul>
<li>New "Invisalign for Kids" brand consumer campaign educates parents of younger children about the benefits of Invisalign&#xAE; clear aligners</li>
<li>New Kids and Teens Invisalign "Growing Patients" professional campaign supports doctors with information including a full range of dedicated products, tools, and treatment options across the Invisalign portfolio that explains how Invisalign treatment specifically meets the needs of growing patients at the stages of their development</li>
<li>New campaigns are part of Align's year-long 20 million smilestone celebration, and feature Invisalign innovation helping doctors transform over 5.8 million kids, teens, and growing patient smiles</li>
</ul>

Reported Earlier, Align Technology Launches Integrated Campaign Highlighting Invisalign Clear Aligner Solutions For Kids, Teens, And Growing Patients

<ul>
<li>Invisalign Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders.</li>
<li>With Invisalign First&#x2122; aligners and Invisalign&#xAE; Palatal Expanders, Align Technology now provides doctors with a full early intervention treatment solution, including both skeletal (orthopedic) and dental (orthodontic) arch expansion.</li>
</ul>

Reported Earlier, Align's Invisalign Palatal Expander System Cleared By NMPA, Set For Commercial Launch In China In Second Half Of 2025

Move over, dividends &#8211; corporate America is in love with itself again. According to JPMorgan strategist Nikolaos Panigirtzoglou, U.S. corporate share buybacks surged in April, marking the strongest monthly pace in years and reinforcing their role as a stabilizing force <a href="https://www.benzinga.com/topic/volatility">in volatile markets</a>.
May has kicked off with a fresh surge of stock buyback announcements, and it's not just a sprinkle &#8211; it's a full-blown cash confetti storm. Repurchase plans announced since April 1 now add up to $262 billion, suggesting companies are favoring ploughing extra cash into buybacks over, say, dividend payments.
Panigirtzoglou notes that this contrarian pattern &#8211; where buybacks ramp up following equity market corrections &#8211; was similarly evident during the Silicon Valley Bank crisis two years ago (the SVB collapsed in March 2023) and the early stages of the Ukraine war.
He notes that corporate repurchases complemented a rebound in equity-focused hedge fund positioning, which had previously de-risked in February and March, further amplifying April&#8217;s V-shaped equity recovery.
Read Also: <a href="https://www.benzinga.com/25/05/45284152/coin-vs-mara-which-crypto-stock-chart-has-the-bullish-edge-before-q1-earnings-drop">COIN Vs. MARA: Which Crypto Stock Chart Has The Bullish Edge Before Q1 Earnings Drop?</a>
<h2 class="wp-block-heading">Apple, Alphabet, Wells Fargo Leading Corporate Buybacks</h2>
Leading the parade is Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), flexing its financial muscles with a jaw-dropping $100 billion buyback—because, apparently, having a $2.7 trillion market cap wasn't enough self-confidence. This is no fluke; it's an "additional" buyback, which means Apple's just topping off a long-standing habit of hoarding its own stock like it&#8217;s going out of style.
Hot on its heels is Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a $70 billion share repurchase. Google may have axed cookies, but it's still baking up returns for shareholders in bulk.
Not to be outdone, Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is pouring $40 billion into its own stock. After years of reputational rehab, the bank seems ready to bet on itself &#8211; in a very big way.
And it&#8217;s not just the mega-caps feeling themselves. KLA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) dropped a $5 billion mic, Dick's Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) entered the <a href="https://www.benzinga.com/25/03/44246625/dicks-sporting-beats-q4-earnings-stock-falls-amid-soft-outlook">game with $3 billion</a>, and Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) is scooping up $3.5 billion of its shares &#8211; proving oil profits aren't just for gas stations and exec bonuses.
<h2 class="wp-block-heading">Tech&#8217;s Buyback Binge</h2>
Tech is clearly in a buyback binge: Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) <a href="https://www.benzinga.com/news/buybacks/25/04/44674899/broadcom-stock-jumps-on-10-billion-buyback-authorization">announced $10 billion</a> in early April, and Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) followed suit with its own <a href="https://www.benzinga.com/news/buybacks/25/03/44218819/applied-materials-hikes-dividend-for-8th-year-greenlights-10-billion-buyback-to-reward-investors">$10 billion plan</a>. 
Meanwhile, Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) flashed its smile with a fresh $1 billion authorization, maybe to offset Invisalign's market volatility.
<h2 class="wp-block-heading">Consumer Stocks &#8211; Not Far Behind</h2>
There's also action in the consumer and industrial space. Graphic Packaging Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>), Ingersoll Rand Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>), and Cirrus Logic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) all made $500 million–$1.5 billion commitments. 
Even MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) got in on the game with a $2 billion plan &#8211; perhaps betting on itself while its visitors bet on the slots.
The pattern is clear: buybacks are back with a vengeance. Whether it&#8217;s to boost EPS, signal confidence, or fend off activist investors, companies are scooping up shares at a pace that has investors sitting up &#8211; and short sellers sweating.
Bottom line? When the biggest names in business are buying their own stock, it might be time for investors to take notice—before the buyback wave pushes prices even higher.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/05/45283751/bill-gates-called-steve-jobs-genius-in-a-way-you-cant-explain-and-said-i-dont-know-somebody-whos-just-like-him-while-reflecting-on-their-decades-long-collaboration-and-rivalry">Bill Gates Called Steve Jobs A &#8216;Genius In A Way You Can&#8217;t Explain,&#8217; Says &#8216;I Don&#8217;t Know Anybody Who&#8217;s Just Like Him&#8217; While Reflecting on Their Decades-Long Collaboration and Rivalry</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Buybacks

Tech

Trading Ideas

AAPL

AMAT

AVGO

CRUS

GOOG

GOOGL

KLAC

SHEL

Apple, Alphabet Lead $262B Buyback Binge On Wall Street

Align Technology, Inc. ("Align") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) a leading global medical device company that designs, manufactures, and sells the Invisalign&#xAE; System of clear aligners, iTero&#x2122; intraoral scanners, and exocad&#x2122; CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has authorized a new stock repurchase program. Under the new program, Align may purchase up to $1.0 billion of its common stock over the next three years. The company's prior $1 billion authorization approved in January 2023 was completed on May 1, 2025 (with settlement on May 2, 2025).

Align Technology Board Approves $1B Stock Repurchase Over Next Three Years

Wells Fargo analyst Vik Chopra maintains Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $255 to $246.

Wells Fargo Maintains Overweight on Align Technology, Lowers Price Target to $246

Piper Sandler analyst Jason Bednar reiterates Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and raises the price target from $235 to $250.

Reiteration

Piper Sandler Reiterates Overweight on Align Technology, Raises Price Target to $250

Evercore ISI Group analyst Elizabeth Anderson maintains Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and raises the price target from $165 to $200.

Evercore ISI Group Maintains Outperform on Align Technology, Raises Price Target to $200

Needham analyst David Saxon reiterates Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) from Hold to Hold.

Needham Reiterates Hold on Align Technologyto Hold

Align Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/04/b45117265/align-technology-announces-first-quarter-2025-financial-results">from the quarter.&nbsp;</a>
The Details:&nbsp;Align Technology reported quarterly earnings of&nbsp;$2.13&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$1.99.&nbsp;Quarterly revenue of&nbsp;$979.26 million beat the consensus estimate of&nbsp;$975.91 million.
Read Next: <a href="https://www.benzinga.com/news/management/25/04/45084982/sofi-brings-crypto-back-after-trump-policy-changes?utm_source=articleShare">SoFi Brings Crypto Back After Trump Policy Changes&nbsp;</a>
Clear Aligner volume of 642,300 cases increased 2.2% sequentially and was up 6.2% year-over-year. Clear Aligner volume for teens and growing patients of 225,800 increased 4.5% sequentially and 13.3% year-over-year. 
Clear Aligner first-quarter revenues of $796.8 million decreased 2.5% year-over-year. Imaging Systems and CAD/CAM Services revenues of $182.4 million increased 1.2% year-over-year.
&#8220;I am pleased to report first quarter revenues, operating margin, and earnings in line with our outlook. Fiscal 2025 is off to a good start with Q1 Clear Aligner volumes up both sequentially and year-over-year, reflecting strength in both the teens and adult patient segments, across all regions, driven by year over year strength across the Asia Pacific and EMEA regions, and growth in North America,&#8221; said CEO Joe Hogan. 
Outlook:&nbsp;Align sees second-quarter revenue in a range of $1.05 billion to $1.07 billion, versus the $1.06 billion estimate. 
ALGN Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Align Technology stock was up 10.21% after-hours at $191 at publication on Wednesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/45076599/sell-in-may-and-go-away-only-in-bear-markets-one-expert-says?utm_source=articleShare">&#8216;Sell In May And Go Away?&#8217; Only In Bear Markets, One Expert Says&nbsp;</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Align Technology Stock Rallies After Q1 EPS, Revenues Beat Estimates

Q2'25:
•We expect Q2'25 worldwide revenues to be in the range of $1,050M to $1,070M, up sequentially from Q1'25.
•We expect Q2'25 Clear Aligner volume to be up sequentially and Q2'25 Clear Aligner ASPs to also be up sequentially, due to favorable foreign exchange at current spot rates, partially offset by the continued product mix shift to non-comprehensive clear aligner products with lower list prices.
•We expect Q2'25 Systems and Services revenues to be up sequentially as we continue to ramp up the iTero Lumina&#x2122; scanner with restorative software.
•We expect Q2'25 worldwide gross margin to be up sequentially primarily from higher ASPs and Clear Aligner volume.
•We expect our Q2'25 GAAP operating margin and Q2'25 non-GAAP operating margin to be up sequentially by approximately 3 points each for GAAP and non-GAAP operating margin.
 &nbsp;

Align Technology Sees Q2 Sales $1.050B-$1.070B vs $1.06B Est

Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.99 by 7.04 percent. This is a 0.47 percent decrease over earnings of $2.14 per share from the same period last year. The company reported quarterly sales of $979.26 million which beat the analyst consensus estimate of $975.91 million by 0.34 percent. This is a 1.82 percent decrease over sales of $997.43 million the same period last year.

Earnings Beats

Align Tech Q1 Adj. EPS $2.13 Beats $1.99 Estimate, Sales $979.26M Beat $975.91M Estimate

Press Releases

Invisalign® Palatal Expander System by Align Technology Now Approved in China for Skeletal and Dental Expansion in Growing Patients

Align Technology Launches Professional Marketing Initiative Featuring Doctors at the Forefront of Digital Orthodontics and Their Stories in Transforming More Than 20M Smiles With Invisalign® Aligners

Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research

Align Technology Launches Integrated Consumer and Professional Brand Campaign Focused on Invisalign® Treatment for Kids and Teens

Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign® Asia Pacific (APAC) Summit

Align Technology to Announce Second Quarter 2025 Results on July 30, 2025

Britt Vitalone Joins Align Technology Board of Directors

Align Technology's Invisalign® Brand Brings Teen Confidence and Smiles in First-Time Film Collab With Disney's "Freakier Friday"

Operation Smile Announces Align Technology as Title Sponsor of International Student Leadership Conference

Comments

Align Technology

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL